Progesterone Receptor anticorps (pSer190)

N° du produit ABIN361517

Détail du produit anti-Progesterone Receptor anticorps

Antigène: Progesterone Receptor (PGR)

Épitope: pSer190

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Progesterone Receptor est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Specificité: Specific for the ~90k PR-A isoform and the ~120k PR-B isoform phosphorylated at Ser190. Immunolabeling is blocked by the phosphopeptide used as antigen but not by the corresponding dephosphopeptide.

Réactivité croisée: Humain

Purification: Protein G purified culture supernatant

Immunogène: Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser190 conjugated to KLH

Clone: 1154

Isotype: IgG1

Information d'application

Indications d'application: Recommended Dilution: WB: 1:1000 IHC (frozen sections, unpublished observations): 1:1000 Quality Control: Western blots performed on each lot.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 100 μL in 10 mM HEPES (  pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.

Stock: -20 °C

Détails sur Progesterone Receptor

Antigène: Progesterone Receptor (PGR)

Autre désignation: PGR (PGR Produits)

Synonymes: anticorps NR3C3, anticorps PR, anticorps 9930019P03Rik, anticorps BB114106, anticorps ENSMUSG00000074510, anticorps PR-A, anticorps PR-B, anticorps XPR-1, anticorps pgr, anticorps xpr-2, anticorps LOC443444, anticorps PGR, anticorps pg, anticorps pr, anticorps gb:dq017620, anticorps progesterone receptor, anticorps progesterone receptor L homeolog, anticorps PGR, anticorps Pgr, anticorps pgr.L, anticorps pgr

Sujet: There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000, Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser190 and Ser294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor. Anti-Phospho Ser190 Progesterone Receptor Western blot of whole cell T47D lysate prepared from cells that had been inubated in the presence of the synthetic progestin agonist R5020 (500 nM) showing specific immunolabeling of the ~90k PR-A isoform and the ~120 PR-B isoform of the progesterone receptor phosphorylated at Ser190. The immunolabeling is specifically blocked by the phosphopeptide used as the antigen (not shown).

Poids moléculaire: 90/120 kDa

ID gène: 5241

UniProt: P06401

Pathways: Nuclear Receptor Transcription Pathway, Intracellular Steroid Hormone Receptor Signaling Pathway, Steroid Hormone Mediated Signaling Pathway, Smooth Muscle Cell Migration